Literature DB >> 31764758

Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.

.   

Abstract

A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women's cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li-Fraumeni syndrome, Cowden syndrome, Peutz-Jeghers syndrome, and hereditary diffuse gastric cancer. A hereditary cancer risk assessment is the key to identifying patients and families who may be at increased risk of developing certain types of cancer. Assessments should be performed by obstetrician-gynecologists or other obstetric-gynecologic care providers and should be updated regularly. An assessment includes information on personal and family history, including pathology, imaging reports, and evaluation of other medical risk factors for cancer. If a hereditary cancer risk assessment suggests an increased risk of a hereditary cancer syndrome, referral to a specialist in cancer genetics or a health care provider with expertise in genetics is recommended for expanded gathering of family history information, risk assessment, education, and counseling, which may lead to genetic testing and tailored cancer screening or risk reduction measures, or both. Currently, genetic testing is guided by personal history, family history, pedigree analysis and, in some cases, risk models that may include pathology reports and confirmation of cancer diagnoses with medical records, death certificates, or both. Counseling before and after genetic testing is an important part of the process to discuss rationale for any genetic testing, disclose results, define other cancer risks, identify educational needs, and secure referrals if necessary for ongoing management. This revision includes updates related to hereditary breast and ovarian cancer, cascade testing, and referrals to genetics specialists.

Entities:  

Mesh:

Year:  2019        PMID: 31764758     DOI: 10.1097/AOG.0000000000003562

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer.

Authors:  Stacy W Gray; Rebecca A Ottesen; Madeline Currey; Mihaela Cristea; Janet Nikowitz; Susan Shehayeb; Vanessa Lozano; Julie Hom; Julie Kilburn; Lisa N Lopez; Sam Wing; Ernesto Sosa; Jenny Shen; Michael Morris; Bedros Dilsizian; Thomas Joseph; James Shen; Camille Adeimy; Tanyanika Phillips; Bahareh Bahadini; Joyce C Niland
Journal:  JCO Clin Cancer Inform       Date:  2022-09

2.  Genetic Characterization of Hereditary Cancer Syndromes Based on Targeted Next-Generation Sequencing.

Authors:  Pelin Ercoskun; Cigdem Yuce Kahraman; Guller Ozkan; Abdulgani Tatar
Journal:  Mol Syndromol       Date:  2021-11-04

3.  Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.

Authors:  Sonya Reid; Sydney Cadiz; Tuya Pal
Journal:  Curr Breast Cancer Rep       Date:  2020-05-19

4.  Interest in Cancer Predisposition Testing and Carrier Screening Offered as Part of Routine Healthcare Among an Ethnically Diverse Sample of Young Women.

Authors:  Kimberly A Kaphingst; Jemar R Bather; Brianne M Daly; Daniel Chavez-Yenter; Alexis Vega; Wendy K Kohlmann
Journal:  Front Genet       Date:  2022-04-14       Impact factor: 4.772

5.  "I have always lived with the disease in the family": family adaptation to hereditary cancer-risk.

Authors:  Eliana Silva; Pedro Gomes; Paula M Matos; Eunice R Silva; João Silva; Catarina Brandão; Fernando Castro; Maria Carolina Neves; Célia M D Sales
Journal:  BMC Prim Care       Date:  2022-04-23

6.  Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.

Authors:  Julie O Culver; Yael Freiberg; Charité Ricker; Jacob G Comeaux; Emmeline Y Chang; Victoria Banerjee; Duveen Sturgeon; Ilana Solomon; Josie Kagey; Mariana G Dobre; Joseph Carey; Azadeh Carr; Stephanie Cho; Janice Lu; Irene M Kang; Ketan Patel; Alicia Terando; Jason C Ye; Ming Li; Caryn Lerman; Darcy Spicer; Maria Nelson
Journal:  Ann Surg Oncol       Date:  2022-09-26       Impact factor: 4.339

Review 7.  Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.

Authors:  David Chelmow; Mark D Pearlman; Amy Young; Laura Bozzuto; Sandra Dayaratna; Myrlene Jeudy; Mallory E Kremer; Dana Marie Scott; Julia Sage O'Hara
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

8.  Serum Lysyl Oxidase Levels and Lysyl Oxidase Gene Polymorphism in Ovarian Cancer Patients of Eastern Indian Population.

Authors:  Suchitra Kumari; A Raj Kumar Patro; Baijayantimala Mishra; Saubhagya Kumar Jena; Sweta Singh
Journal:  Diagnostics (Basel)       Date:  2021-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.